Skip to main content

Latest collections open to submissions

We are welcoming submissions to the following article collections.


Microbiome in the First 1000 Days of Life

Guest Edited by Souhaila Al Khodor
Open until 10 December 2025


Harnessing Innovative Machine Learning Techniques to Combat Drug Resistance in Solid Tumors

Guest Edited by Wendy Mao and Hao Zhang
Open until 28 November 2025


Regeneration and Remodeling after Brain Injury: Implications for Stem Cell Therapy

Guest Edited by Hailiang Tang and Francisco Silva
Open until 19 December 2025


Prevention and Early Diagnosis of Breast Cancer

Guest Edited by Monica Pernia Marin, Caren Greenstein, and Mary Salvatore
Open until 31 August 2026

Article Collections

Fibrosis and Cancer Intersection

This article collection aims to clarify the correlation between tissue fibrosis and cancer origination and progression. 

"Planeterranean" Diet: Globally Extending the Health Benefits of the Mediterranean Diet

This article collection focuses on the challenge of transferring the Mediterranean Diet key concept to non-Mediterranean areas within a “One Health” perspective.

Join the Editorial Board

We are recruiting new Associate Editors to join our international Editorial Board. Learn more about the role and how to apply here.

Meet the Editors

Get to know the Editors behind Journal of Translational Medicine! 

Articles

Featured Research: Development and multi-cohort validation of a machine learning-based simplified frailty assessment tool for clinical risk prediction

This research study has introduced a streamlined frailty assessment tool powered by machine learning, designed to help clinicians quickly identify at-risk patients using just eight common clinical variables. Validated across multiple international cohorts, the tool outperforms traditional frailty indices in predicting outcomes like kidney disease progression, cardiovascular events, and mortality—making it a practical and powerful addition to everyday healthcare settings.

Featured Review: Influence of OCT2 gene variants on metformin efficacy in type 2 diabetes: insights into pharmacogenomics and drug interactions

Analyzed in this recent review, metformin, a common treatment for type 2 diabetes, shows wide variability in patient response, largely due to genetic differences in drug transporters like OCT2. Variations in the OCT2 gene (SLC22A2) can affect metformin’s uptake in the kidneys, altering its clearance and effectiveness. Drug interactions may further impact its pharmacokinetics, especially in patients with multiple conditions. Considering genetic testing could improve dosing and treatment outcomes.

Top trending articles


Check out the
most discussed articles from the previous month!

Journal of Translational Medicine has launched In Review, a new option that provides authors with on-demand information on the status of their manuscript, enables them to share their work with funders and their research community, and allows their colleagues to comment and collaborate - all whilst their manuscript is under review.

Read More

Read our blogs

From discovery to real-world applications

In this Q&A, Dr Florence Bietrix, Section Editor, talks to us about the importance of the journey from discovery to real-world application and how the Translational Process section is contributing directly to achieving the Sustainable Development Goals 3 (Good Health & Wellbeing), 5 (Gender Equality), and 10 (Reduced Inequalities).

Meet the SDG3 Researcher: Dr Souhaila Al Khodor

In this Q&A, Dr Al Khodor discusses her career and research focus on women's and infants health, her efforts to contribute directly to achieving SDG3, and the Microbiome in the First 1000 Days of Life collection launch.

Aims and scope

Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.

The journal covers all areas of translational medicine but also has several special sections:

Editor-in-Chief: Francesco Marincola, USA

Francesco (Franco) Marincola is the Chief Scientific Officer of Translational and Advanced Medicine (TAM) Biosciences, Nashville, TN.  Franco brings over 30 years of research and development experience in immunology, oncology and cell therapy.

Most recently, Franco served as Chief Scientific Officer at Sonata Therapeutics, Boston, Massachusetts. Before he was Senior Vice President and Global Head of Research at Kite Pharma where he led the research organization to identify novel therapies for hematologic malignancies and solid tumors. Prior to Kite, he was President and Chief Scientific Officer at Refuge Biotechnologies, where he developed research strategies for adoptive cell therapy products and led therapeutic programs based on nuclease deactivated CRISPR circuits. Prior to Refuge, Franco was Distinguished Research Fellow in Immune Oncology at AbbVie, and Chief Research Officer at Sidra Medical and Research Centre.

Before joining the biopharma industry, Franco spent more than two decades at the National Institutes of Health (NIH) and National Cancer Institute (NCI), as a tenured senior investigator in cancer immunotherapy and biomarker research and as Chief Infectious Disease and Immunogenetics Investigator at the NIH Clinical Center.

Franco is the former President of the Society for Immunotherapy of Cancer (SITC). He currently serves as Editor-in-Chief for multiple peer-reviewed publications, including Journal of Translational Medicine, and Immunotherapy, and is the author of more than 700 peer-reviewed publications. 

Franco is also a fiction writer and his collections can be found at: 
https://wordpress.com/home/authorfrancomarincola.wordpress.com.

Franco received his M.D. from the University of Milan, Italy and completed his residency and training in immunology at Stanford University, California.

Annual Journal Metrics

  • Citation Impact 
    Journal Impact Factor: 7.5 (2024)   
    5-year Journal Impact Factor: 7.0 (2024)    
    Source Normalized Impact per Paper (SNIP): 1.321 (2024)    
    SCImago Journal Rank (SJR): 1.997 (2024)

    Speed 
    Submission to first editorial decision (median days): 11
    Submission to acceptance (median days): 99

    Usage 2024
    Downloads: 7,617,512
    Altmetric mentions: 6,383